We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XWhite Paper
November 4, 2015
In 2014, global sales for monoclonal antibodies (mAbs) and mAb-derived products reached $75 billion dollars, which according to US BioProcess Technology Consultants, comprised more than half of the total biopharmaceutical market. It’s not just about the money, as Eppendorf has shown the value of mAbs in treating disease and carrying out diagnostics and research.
Download to find out more.